# Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium

> **NCT04008121** · EARLY_PHASE1 · RECRUITING · sponsor: **MediBeacon** · enrollment: 10 (estimated)

## Conditions studied

- Retinopathy
- Retinal Vein Occlusion
- Diabetic Retinopathy
- Macular Degeneration

## Interventions

- **COMBINATION_PRODUCT:** Fluorescein sodium and Zeiss FF450 fundus camera
- **COMBINATION_PRODUCT:** MB-102 and Zeiss FF450 fundus camera
- **COMBINATION_PRODUCT:** Fluorescein sodium and commercially available optical angiography imaging system
- **COMBINATION_PRODUCT:** MB-102 and commercially available optical angiography imaging system

## Key facts

- **NCT ID:** NCT04008121
- **Lead sponsor:** MediBeacon
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-06
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04008121

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04008121, "Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04008121. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*